The FDA approved bepirovirsen, the first antisense oligonucleotide for chronic hepatitis B, offering a new treatment with functional cure potential.
|Articles|September 11, 2020
AJMC® in the Press, September 11, 2020
Author(s)AJMC Staff
Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.
Advertisement
An opinion piece published by
Advertisement
Related to this article
A real-world trial found 42.6% of patients with severe hand eczema cleared on oral alitretinoin.
AMCP Nexus 2026 brings managed care leaders to San Diego October 26-29 to tackle Medicare negotiation, drug pricing policy, AI, and patient access.
IDWeek 2026 posters describe a rule-based tool classifying about 1 in 5 patients with cUTI as outpatient-eligible and 5 clusters with varied LOS.
An international eDelphi panel of 62 dermatologists agreed on a 2-step algorithm for tapering psoriasis biologics.
Real-world data from CHEST 2026 show ETI improved lung function and BMI in children with CF aged 6 to 11, with the most gains in F508del homozygotes.
Birth centers are unavailable in 10 states, and 39% of birth center births are self-pay, as licensing and Medicaid pay limit access, a report finds.
Narcolepsy and idiopathic hypersomnia can go undiagnosed for years, and Epworth and RU-SATED screening help clinicians spot true sleepiness sooner.
Advertisement
Advertisement
Trending on AJMC
1
Awareness Gaps Drive Narcolepsy, IH Delays: Logan Schneider, MD
2
Administrative Burden Keeps Clinicians From Bedside: Amy Morris, MD
3
Extension Studies in TPIP Show Promise in PAH, PH-ILD
4
International Panel Agrees on Framework for Tapering Psoriasis Biologics
5